The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.
Kuan-Yu TsengChiann-Yi HsuYu-Hsuan ShihHsin-Chen LinYou-Cheng LiChieh-Lin Jerry TengCheng-Wei ChouPublished in: Therapeutic advances in medical oncology (2024)
Concomitant use of ACEIs/ARBs in patients with pancreatic cancer resulted in significantly better 12-month EFS. Age, performance status, disease status, and higher CA19-9 levels were independent predictors of survival. The combination strategy might provide better treatment outcomes in patients with PDAC.
Keyphrases